Loading...

MedXY AI/MedXY News/Tag: breast cancer

MedXY News

EnglishTag

breast cancer

68 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

A New Era in Targeted Therapy: The Journey of Datopotamab Deruxtecan in HR+/HER2- Breast Cancer

Explore the Phase 3 TROPION-Breast01 study results, detailing how the antibody-drug conjugate datopotamab deruxtecan offers a superior alternative to standard chemotherapy in advanced HR+/HER2- breast cancer through improved progression-fre

Section: newsJan 9, 2026

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

Improving Persistence: Dose Escalation Enhances Adjuvant Abemaciclib Tolerability in Early Breast Cancer

The Phase II TRADE trial demonstrates that a stepwise dose escalation of abemaciclib significantly improves drug tolerability and reduces early discontinuation rates in patients with high-risk HR-positive, HER2-negative early breast cancer

Section: news

Jan 9, 2026

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression,

Section: newsJan 9, 2026

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors

A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for ad

Section: newsJan 9, 2026

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial

The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhance

Section: Hematology-OncologyJan 8, 2026

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?

Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?

The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.

Section: newsJan 8, 2026

Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy

Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy

The OPBC-07/microNAC study suggests that axillary lymph node dissection can be safely omitted in many breast cancer patients with residual micrometastases post-neoadjuvant chemotherapy, provided nodal radiotherapy is used, though triple-neg

Section: General SurgeryJan 6, 2026

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status

A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.

Section: NeurologyDec 17, 2025

Broad Genetic Testing Reveals Hidden Breast Cancer Risk in Women Without Family History

Broad Genetic Testing Reveals Hidden Breast Cancer Risk in Women Without Family History

The WISDOM trial found that 3.1% of women without breast cancer carried pathogenic variants in key susceptibility genes, many outside existing testing guidelines.

Section: newsDec 17, 2025

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets

Section: newsNov 25, 2025

Preoperative Single‑Fraction Ablative Radiotherapy for Early HR+ Breast Cancer: Low Toxicity, High Pathologic Responses with Delayed Surgery

Preoperative Single‑Fraction Ablative Radiotherapy for Early HR+ Breast Cancer: Low Toxicity, High Pathologic Responses with Delayed Surgery

A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months o

Section: newsNov 19, 2025

Hormonal Contraceptive Progestin Content Strongly Modifies Breast Cancer Risk in Adolescents and Premenopausal Women

Hormonal Contraceptive Progestin Content Strongly Modifies Breast Cancer Risk in Adolescents and Premenopausal Women

A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute e

Section: newsNov 12, 2025

SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer

SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer

The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall s

Section: newsNov 10, 2025

Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial

Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial

The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.

Section: NeurologyNov 1, 2025

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survi

Section: OB/GYN & Women's HealthOct 25, 2025

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.

Section: CardiologyOct 24, 2025

Enhancing Fertility Preservation and Ovarian Function in Young Women with Breast Cancer: Insights from International Prospective Studies

Enhancing Fertility Preservation and Ovarian Function in Young Women with Breast Cancer: Insights from International Prospective Studies

This article reviews a joint analysis of the Joven & Fuerte and PREFER studies, highlighting disparities in fertility preservation strategies among Mexican and Italian young women with breast cancer, and discusses implications for clinical

Section: newsOct 23, 2025

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

Section: Hematology-OncologyOct 19, 2025

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.

Section: OB/GYN & Women's HealthOct 19, 2025

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

Section: newsOct 15, 2025

Prev 1 2 3 4 Next

MedXY News - breast cancer